April 5, 2019

#ReSViNET , the Respiratory Syncytial Virus Network, selected the recent publication in AJRCCM on the SynGEM Phase I clinical trial as paper of the month March. The study which was executed by Imperial College London, showed that #SynGEM is safe and capable of inducing long term immune responses. A commentary published in the same journal suggested to test the vaccine in a human challenge study. The author manuscript can now be downloaded free of charge from the ReSViNET website

Please reload

Virtuvax News

  • LinkedIn Social Icon
  • Twitter Social Icon

© 2016-2017 by Virtuvax BV, The Netherlands